Literature DB >> 1980800

Malaria and its treatment in rural villages of Aboh Mbaise, Imo State, Nigeria.

G C Ejezie1, E N Ezedinachi, E A Usanga, E I Gemade, N W Ikpatt, A A Alaribe.   

Abstract

We examined the malaria situation among 489 children under 5 years of age in the rural villages of Aboh Mbaise, Nigeria, using a combination of a standard questionnaire technique and laboratory diagnosis to confirm clinical observations. The results show a high prevalence rate of 52.8% for Plasmodium falciparum in this area. The geometric mean parasite density (GMPD) was 19,361.4/mm3. The proportion of children with fever and/or parasitaemia was not related to age, although the numbers in the febrile group appeared to increase with age. Using 37.5 degrees C as the threshold for fever, 48.7% of the heavily infected group (more than 1000/mm3) were afebrile while 51.3% were febrile. High grade temperatures above 38 degrees C were associated with high parasitaemia above 10,000 parasites/mm3. Of the 911 children who died in the area within the last five years, 22.4% died of fever of unknown origin, 39.7% from malaria, 22.5% from convulsion, 10.5% from diarrhoea and 4.6% from cough. Chloroquine is the drug of choice for the treatment of malaria and there were many cases of drug abuse, and use of sub-curative doses prescribed by non-medically qualified staff.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980800     DOI: 10.1016/0001-706x(90)90061-4

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  10 in total

Review 1.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 2.  The state of health economic evaluation research in Nigeria: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Economic implications of resistance to antimalarial drugs.

Authors:  M Phillips; P A Phillips-Howard
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

4.  Antimalarial drug use among caregivers in Ghana.

Authors:  Benjamin K Abuaku; Kwadwo A Koram; Fred N Binka
Journal:  Afr Health Sci       Date:  2004-12       Impact factor: 0.927

Review 5.  Mixed-species Plasmodium infections of humans.

Authors:  F E McKenzie; W H Bossert
Journal:  J Parasitol       Date:  1997-08       Impact factor: 1.276

6.  Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.

Authors:  Peter Usman Bassi; Adeline I Osakwe; Ambrose Isah; Comfort Suku; Musa Kalat; Iliya Jalo; Robinson Daniel Wammanda; Chika Ugochukwu; Olubukula Adesina; Eno Etim Nyong; Frank Osungwu; Shanti Pal; Sylvester Chigozie Nwoasu; Magnus Wallberg; David Coulter
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

7.  Using mixed effects logistic regression models for complex survey data on malaria rapid diagnostic test results.

Authors:  Chigozie Louisa J Ugwu; Temesgen T Zewotir
Journal:  Malar J       Date:  2018-12-05       Impact factor: 2.979

8.  Is chloroquine better than artemisinin combination therapy as first line treatment in adult nigerians with uncomplicated malaria?-A cost effectiveness analysis.

Authors:  Shaibu O Bello; Aminu Chika; Aishatu Y Bello
Journal:  Afr J Infect Dis       Date:  2010

9.  Impact of Plasmodium falciparum and hookworm infections on the frequency of anaemia in pregnant women of rural communities in Enugu, South East Nigeria.

Authors:  Polycarp Uche Agu; Johnbull Sonny Ogboi; Kesiena Akpoigbe; Tochukwu Okeke; Euzebus Ezugwu
Journal:  Pan Afr Med J       Date:  2013-01-18

10.  Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach.

Authors:  Ayodele Jimoh; Oluyemi Sofola; Amos Petu; Tuoyo Okorosobo
Journal:  Cost Eff Resour Alloc       Date:  2007-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.